We are live on ! Find out more
MRNS

Marinus Pharmaceuticals, Inc

Delisted

MRNS was delisted on the 10th of February, 2025.

27 hedge funds and large institutions have $73.2M invested in Marinus Pharmaceuticals, Inc in 2015 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

39% more capital invested

Capital invested by funds: $52.8M → $73.2M (+$20.4M)

29% more funds holding

Funds holding: 2127 (+6)

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
27
Holders Change
+6
Holders Change %
+28.57%
% of All Funds
0.73%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
12
Increased
5
Reduced
4
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CPV
1
Canaan Partners VII
Connecticut
$28.6M
Franklin Resources
2
Franklin Resources
California
$15.1M +$735K +19,671 +6%
NLVP
3
New Leaf Venture Partners
New York
$7.58M +$1.21M +32,311 +25%
PI
4
Putnam Investments
Massachusetts
$3.48M
SFM
5
Sphera Funds Management
Israel
$3.46M +$794K +21,250 +40%
Point72 Asset Management
6
Point72 Asset Management
Connecticut
$2.73M +$2.19M +58,750 New
ACH
7
ArrowMark Colorado Holdings
Colorado
$2.47M +$1.99M +53,161 New
BBA
8
Baker Bros. Advisors
New York
$2.32M
EA
9
Emerald Advisers
Pennsylvania
$2.15M -$1.88M -50,418 -52%
AIC
10
AWM Investment Company
New York
$1.62M -$1.19M -31,834 -48%
Goldman Sachs
11
Goldman Sachs
New York
$1.23M +$836K +22,378 +537%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$421K +$143K +3,821 +72%
Vanguard Group
13
Vanguard Group
Pennsylvania
$379K +$305K +8,175 New
BCM
14
Bridgeway Capital Management
Texas
$348K +$280K +7,500 New
DCM
15
DAFNA Capital Management
California
$259K +$208K +5,580 New
CS
16
Credit Suisse
Switzerland
$252K +$203K +5,437 New
TC
17
TFS Capital
Pennsylvania
$204K +$165K +4,407 New
Morgan Stanley
18
Morgan Stanley
New York
$192K -$156K -4,179 -50%
ARTA
19
A.R.T. Advisors
New York
$192K +$155K +4,149 New
HCM
20
Harvey Capital Management
Florida
$174K
CGT
21
Capital Guardian Trust
California
$48K
BIM
22
BlackRock Investment Management
Delaware
$9K -$1.98K -53 -21%
Wells Fargo
23
Wells Fargo
California
$9K +$7.47K +200 New
UBS Group
24
UBS Group
Switzerland
$8K +$6.76K +181 New
Deutsche Bank
25
Deutsche Bank
Germany
$3K +$2.8K +75 New

MRNS Hedge Fund Activity: Q2 2015 in Review

27 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q2 2015, worth a combined $73.2M — up 39% from $52.8M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new MRNS positions and 6 closed out — a net gain of 6 holders — while 5 added to existing stakes and 4 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $2.19M. The largest seller was Emerald Advisers, cutting an estimated $1.88M.

  • 27 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q2 2015, up from 21 in Q1 2015.
  • Funds reported $73.2M of Marinus Pharmaceuticals, Inc stock for Q2 2015, up 39% quarter-over-quarter.
  • 12 funds opened new Marinus Pharmaceuticals, Inc positions in Q2 2015 and 6 closed out, a net change of +6 holders.
  • The largest Marinus Pharmaceuticals, Inc buyer in Q2 2015 was Point72 Asset Management, an estimated $2.19M added.
  • The largest Marinus Pharmaceuticals, Inc seller in Q2 2015 was Emerald Advisers, an estimated $1.88M sold.

Based on aggregated 13F filings for Q2 2015.